Welcome to the Instem Investor Centre
Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.
Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:
- collect, analyse and report complex scientific data;
- comply with regulatory reporting requirements;
- improve quality, consistency and efficiency of information reporting; and
- reduce the time of critical path R&D activities.
Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.
Instem is a robust business, with net cash and a valuable customer base delivering high levels of recurring revenue. The business continues to increase its strong global market share and is well positioned to take advantage of the structural changes in the drug development industry. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite.
Our recent acquisition of Logos Technologies is an important strategic move into the early phase clinical market. This market represents a significant opportunity as it is much less automated in terms of data capture and analysis than Instem’s core pre-clinical market, and, it also provides avenues for additional cross-sales.